HRAS and hepatocellular carcinoma: Regarding the strong effects of rigosertib on HCC cell lines in vitro (Figures 1–3), qRT-PCR analysis of HRAS and PLK1 expression levels was also performed in HCC cell lines (HepG2, Hep3B, PLC, Huh-7) as compared to primary human hepatocytes (PHH), and revealed marked overexpression of both HRAS (Figure 4E) and PLK1 (Figure 4F) in HCC cells.